Clinical Trials Logo

Cytomegalovirus (CMV) clinical trials

View clinical trials related to Cytomegalovirus (CMV).

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05576805 Completed - Clinical trials for Cytomegalovirus (CMV)

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Solid Organ Transplant (SOT) Participants in Europe and Canada

Start date: June 19, 2023
Phase:
Study type: Observational

The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.

NCT ID: NCT05571137 Completed - Clinical trials for Cytomegalovirus (CMV)

A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

Start date: May 31, 2023
Phase:
Study type: Observational

The main aim of the study is to assess the clinical outcomes of current CMV management across different regions of the world (Europe [EU] and Canada [CAN]). Data will be collected retrospectively from medical charts. No study medicines will be provided to participants in this study.

NCT ID: NCT05137717 Completed - Clinical trials for Cytomegalovirus (CMV)

A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection

Start date: December 23, 2021
Phase: Phase 3
Study type: Interventional

The main aim of the study is to check if treatment with maribavir can protect Japanese people against Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting side effects from it. Japanese recipients of a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT) will take Maribavir tablets two times a day for 8 weeks in this study. During the study, participants will visit their study clinic 18 times as a maximum.

NCT ID: NCT02931539 Completed - Clinical trials for Cytomegalovirus (CMV)

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Start date: December 22, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.

NCT ID: NCT02927067 Completed - Clinical trials for Cytomegalovirus (CMV)

A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants

Start date: April 14, 2017
Phase: Phase 3
Study type: Interventional

This study is about treatment options for cytomegalovirus infections in people who have received stem cell transplants. The main aim of the study is to check if the cytomegalovirus infection can no longer be detected after treatment with marivabir or valganciclovir. Participants will take 2 tablets of marivabir or valganciclovir and 2 tablets of placebo twice a day for 8 weeks. A placebo will look like marivabir or valganciclovir but will not have any medicine in it. After treatment, each participant will be followed up for up to 12 weeks. Participants will visit their study clinic up to 18 times during the study.

NCT ID: NCT02775240 Completed - Clinical trials for Cytomegalovirus (CMV)

Study of SHP620 (Maribavir) in Healthy Adults

Start date: July 21, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan). The study will also look at the safety and tolerability when maribavir is coadministered with digoxin and dextromethorphan versus digoxin and dextromethorphan alone.

NCT ID: NCT01611974 Completed - Clinical trials for Cytomegalovirus (CMV)

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

Start date: July 17, 2012
Phase: Phase 2
Study type: Interventional

This study will assess safety, antiviral activity, and pharmacokinetics of different doses of maribavir administered orally for up to 24 weeks for treatment of CMV infections that are resistant or refractory to treatment with ganciclovir/valganciclovir or foscarnet in recipients of stem cell or solid organ transplants.